The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae700 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Aiden V Brossfield und 9 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Bone Disease Unit, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycation End Products, Advanced, Pyridoxamine, Bone and Bones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: NIH/NIA.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
Patients with type 2 diabetes (T2D) have reduced bone turnover and increased fractures. Advanced glycation end products (AGEs) impair osteoblasts and are implicated in diabetic fractures. Pyridoxamine (PM) is a vitamin B6 metabolite that inhibits formation of AGEs.
Objective
We hypothesized that PM treatment in older patients with T2D, by inhibiting AGEs, would increase bone formation.
Methods
This was a double-blind randomized controlled trial at an academic center. Older women with T2D were included (n = 55). Oral PM 200 mg twice daily for 1 year was given. The primary outcome was the change in the bone formation marker P1NP. Other outcomes were changes in bone resorption, bone mineral density (BMD), HbA1c, and skin autofluorescence (SAF), and in a bone biopsy subgroup, the correlation between bone fluorescent AGEs (fAGEs) and SAF.
Results
P1NP increased 23.0% with PM (95% CI 9, 37; within group P = .028) vs 4.1% with placebo (−9, 17; within group P = .576; between groups P = .056). BMD increased at the femoral neck (PM 2.6 ± 5% vs placebo −0.9 ± 4%; between groups P = .007). Bone resorption markers and SAF did not change. HbA1c decreased (PM −0.38 ± 0.7% vs placebo 0.05 ± 1.7%; between groups P = .04). Within the PM group, the HbA1c change correlated inversely with the % P1NP change (r = −0.50, P = .034). Cortical bone biopsy fAGEs correlated with SAF (r = 0.86, P = .001). Adverse events were similar between groups.
Conclusion
PM tended to increase P1NP in older women with T2D, as well as increasing bone density and reducing HbA1c. Further studies are needed to investigate the potential of PM as a disease mechanism–directed approach to reduce fractures in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Bone Disease Unit, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA.
- Department of Biomedical Engineering, Shirley Ann Jackson, PhD Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
- Rensselaer-Icahn School of Medicine Center for Engineering and Precision Medicine, New York, NY 10029, USA.
ORCID-Profile: Sanchita Agarwal, Bowen Wang, Deepak Vashishth, Mishaela R Rubin
Förderung
- NIH/NIA
Zitieren
APA
Brossfield, A. V., McMahon, D. J., Fernando, J., Omeragic, B., Majeed, R., Agarwal, S., Sroga, G. E., Wang, B., Vashishth, D., & Rubin, M. R. (2025). The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae700
Vancouver
Brossfield AV, McMahon DJ, Fernando J, Omeragic B, Majeed R, Agarwal S, et al. The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae700
BibTeX
@article{Brossfield2025,
author = {Brossfield, Aiden V and McMahon, Donald J and Fernando, Jason and Omeragic, Beatriz and Majeed, Rukshana and Agarwal, Sanchita and Sroga, Grazyna E and Wang, Bowen and Vashishth, Deepak and Rubin, Mishaela R},
title = {The Effects of the AGE Inhibitor Pyridoxamine on Bone in Older Women With Type 2 Diabetes: A Randomized Clinical Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae700}
}
EUVIMED